

APPLICATION No.  
10/046,575

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE  
January 16, 2002

GROUP
Unassigned

**JUN 07 2002**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
b	GOTO et al., "Suppressive Effect of Topically Applied CX-6595, a Novel Diaminouracil Derivative, on the Contact Hypersensitivity Reaction in Various Animal Models", <i>International Archives of Allergy and Immunology</i> , August 28, 2000, pp. 341-348, vol. 123, Basel, Switzerland.					
w	<del>ANTREX Vol 10, No. 3 pp. 155-161</del> <i>not translated</i> .					
B	"Cyclosporin ointment for psoriasis and atopic dermatitis," <i>The Lancet</i> , May 2, 1992, p. 1120, vol. 339.					
w	YAKYOKU, (1996) pp. 31-35, vol. 47, no. 8.					
Examiner Signature				Date Considered	7/10/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

APR 16 2002

SHEET 1 OF 1

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.

018995-452

APPLICATION NO.

10/046,575

APPLICANT

Nishizumi NISHIMUTA et al.

FILING DATE

January 16, 2002

GROUP

Unassigned

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
<i>Y</i>	07304649	A	Japan	11-21-1995		
<i>Y</i>	07025784	A	Japan	01-27-1995		
<i>Y</i>	06227989	A	Japan	08-16-1994		
<i>Y</i>	10007584	A	Japan	01-13-1998		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>Y</i>	BOYD et al., "An investigation of the Immunosuppressive Effects of Niridazole and Metronidazole in Rat and Baboon Heterotopic Cardiac Allograft Models," <i>Transplantation</i> (1981), pp. 326-329, vol. 31, no. 5, Lippincott William & Wilkins, Baltimore, Maryland.
<i>Y</i>	YOURAN, "Summary of Drugs," (1992), pp. 1194-1195, vol. 5.
<i>Y</i>	NIPPON YAKYOKUHO KAISETSUSYO, Explanation of Japanese Codices No. 13 revision, c-2544, 1996.
<i>Y</i>	Report of experimental results made by Dr. Hirahara, dated October 10, 2001.
<i>Y</i>	Kiso to Rinsho, pp. 2693-2700, vol. 31, no. 8, 1997.
<i>Y</i>	"Definition and diagnostic standard of atopic dermatitis," <i>Japanese Society of Dermatology</i> , 1994, p. 1210, vol. 104.
<i>Y</i>	A guideline for the treatment of atopic dermatitis, 2001.
<i>Y</i>	Today's Therapy in Dermatology, 1996, pp. 179-182.
<i>Y</i>	<i>Japanese Journal of Dermatology</i> , 2000, p. 667, vol. 110, No. 4.
<i>Y</i>	HIHU, <i>West Japan Dermatology</i> , 1997, pp. 58-65, vol. 59, published by Ointment study group.
<i>Y</i>	ZASSHI, <i>Journal of the Japanese Medicine</i> , 2001, pp. 53-57, vol. 126, no. 1.
<i>Y</i>	KOSTAKIS et al., "The Immunosuppressive Action of Metronidazole," <i>IRCS Medical Science: Cardiovascular System: Immunology and Allergy: Pharmacology: Surgery and Transplantation</i> , 1997, vol. 142, no. 5.
Examiner Signature	<i>[Signature]</i>
Date Considered	7/10/03.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

(05/01)